Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Часто задаваемые вопросы
В каком секторе работает Evaxion Biotech AS (EVAX)?
Evaxion Biotech AS относится к сектору Здравоохранение.
Какова текущая цена акций Evaxion Biotech AS (EVAX)?
По последним данным, цена акций Evaxion Biotech AS составляет 3,20 $, предыдущее закрытие — 3,18 $. За последнюю торговую сессию акции Evaxion Biotech AS выросли на 0,02 $, что соответствует росту на 0,63%.
Выплачивает ли Evaxion Biotech AS (EVAX) дивиденды?
Нет, Evaxion Biotech AS не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Evaxion Biotech AS (EVAX)?
У компании Evaxion Biotech AS бета 0.254, что указывает на более низкую волатильность по сравнению с рынком в целом.
